Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613928 | 0.86 | GABRA1 (0.37) | GABRA1GABRB1CA1CA2P2RX3 | |
| SCHEMBL25927987 | 0.84 | GABRA1 (0.35) | GABRA1GABRB1 | |
| SCHEMBL27929486 | 0.82 | GABRA1 (0.34) | GABRA1GABRB1P2RX3P2RX2 | |
| SCHEMBL15614474 | 0.81 | GABRA1 (0.37) | GABRA1GABRB1CA1CA2P2RX3 | |
| SCHEMBL22448616 | 0.79 | POLB (0.36) | GABRA1GABRB1P2RX3P2RX2 | |
| SCHEMBL22448601 | 0.79 | GABRA1 (0.45) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL12356926 | 0.79 | P2RX3 (0.48) | P2RX3P2RX2 | |
| SCHEMBL25928014 | 0.76 | GLP1R (0.39) | GABRA1GABRB1 | |
| SCHEMBL22448705 | 0.76 | POLB (0.46) | P2RX3P2RX2 | |
| SCHEMBL12848758 | 0.72 | UHRF1 (0.41) | GABRA1GABRB1CA1CA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2021155841-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-08-12 | — | — | WO | disclosed |